Joaquin Martinez-Lopez1, Juan J. Lahuerta1, François Pepin2, Marcos González3, Santiago Barrio1, Rosa Ayala1, Noemí Puig3, María A. Montalban1, Bruno Paiva4, Li Weng2, Cristina Jiménez3, María Sopena1, Martin Moorhead2, Teresa Cedena1, Immaculada Rapado1, María Victoria Mateos3, Laura Rosiñol5, Albert Oriol6, María J. Blanchard7, Rafael Martínez8
1Hospital Universitario 12 de Octubre, Madrid, Spain
2Sequenta, Inc., San Francisco, CA
3Hospital Universitario de Salamanca-IBSAL, IBMCC-CSIC, Salamanca, Spain
4Clínica Universitaria de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
5Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
6Hospital Germans Trias i Pujol, Barcelona, Spain
7Hospital Ramón y Cajal, Madrid, Spain
8Hospital Clínico de Madrid, Madrid, Spain
Tóm tắt
Key Points
MRD assessment by sequencing is prognostic of TTP and OS in multiple myeloma patients. Among patients in complete response, MRD assessment by sequencing enables identification of 2 distinct subgroups with different TTP.
